Free Trial

Spero Therapeutics Q4 2023 Earnings Report

Spero Therapeutics logo
$0.74 -0.03 (-3.72%)
As of 12:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Spero Therapeutics EPS Results

Actual EPS
$0.96
Consensus EPS
-$0.18
Beat/Miss
Beat by +$1.14
One Year Ago EPS
N/A

Spero Therapeutics Revenue Results

Actual Revenue
$73.52 million
Expected Revenue
$19.40 million
Beat/Miss
Beat by +$54.12 million
YoY Revenue Growth
N/A

Spero Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Spero Therapeutics Earnings Headlines

Spero Therapeutics reports Q4 EPS (38c), consensus (31c)
[OPEN NOW] New rules to trade options with.
Here’s an update that could make your entire year. But first, a question. Could you get better wins if you applied a new set of rules to your trade? For example, when you meet your criteria to take a trade, could you improve your results by taking the same trade differently? From the audit I just did, it turns out the answer is a resounding YES! I applied a new set of rules to 100 live published trades from 2024. These 100 trades already got a whopping 69% win rate – taking a $10k model account risking 10% per trade to $63,304. But what happened when we applied these new rules? We got an 85.1% win rate and sent the same $10k account risking 10% per trade to over $200k!
See More Spero Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spero Therapeutics and other key companies, straight to your email.

About Spero Therapeutics

Spero Therapeutics (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

View Spero Therapeutics Profile

More Earnings Resources from MarketBeat